Last reviewed · How we verify
ICG R15 — Competitive Intelligence Brief
marketed
Near-infrared fluorescent contrast agent
Surgery/Hepatology
Small molecule
Live · refreshed every 30 min
Target snapshot
ICG R15 (ICG R15) — Seoul National University Hospital. ICG R15 is an indocyanine green (ICG) derivative that fluoresces in the near-infrared spectrum for real-time visualization of liver function and blood flow during surgery.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| ICG R15 TARGET | ICG R15 | Seoul National University Hospital | marketed | Near-infrared fluorescent contrast agent | ||
| Indocyanine Green Drug | Indocyanine Green Drug | Theodor Bilharz Research Institute | marketed | Near-infrared fluorescent contrast agent |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (Near-infrared fluorescent contrast agent class)
- Seoul National University Hospital · 1 drug in this class
- Theodor Bilharz Research Institute · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- ICG R15 CI watch — RSS
- ICG R15 CI watch — Atom
- ICG R15 CI watch — JSON
- ICG R15 alone — RSS
- Whole Near-infrared fluorescent contrast agent class — RSS
Cite this brief
Drug Landscape (2026). ICG R15 — Competitive Intelligence Brief. https://druglandscape.com/ci/icg-r15. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab